ADMA Biologics Inc ADMA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
ADMA Biologics, Inc. (ADMA) Investors: August 10, 2026, Deadline in Securities Fraud Class Action Lawsuit – Contact Kessler Topaz Meltzer & Check, LLP
-
Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
-
ADMA UPCOMING DEADLINE : The Gross Law Firm Alerts ADMA Biologics, Inc. Stockholders of Securities Class Action - Contact the Firm
-
Deadline Approaching: ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
-
Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
-
ADMA BIOLOGICS, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates ADMA Biologics, Inc.’s Directors and Officers for Breach of Fiduciary Duties – ADMA
-
ADMA INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages ADMA Biologics, Inc. (ADMA) Shareholders To Inquire About Securities Fraud Class Action
Trading Information
- Previous Close Price
- $8.58
- Day Range
- $8.39–8.68
- 52-Week Range
- $7.21–20.46
- Bid/Ask
- $8.40 / $8.80
- Shares Outstanding
- 231.77M
- Market Cap
- $1.95B
- Volume/Avg
- 3M / 7M
Key Statistics
- Price/Earnings (Normalized)
- 11.55
- Price/Sales
- 3.92
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 1.68%
Company Profile
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 647
- Website
- https://www.admabiologics.com
Valuation
|
Metric
|
ADMA
|
|---|---|
Price/Earnings (Normalized) | 11.55 |
Price/Book Value | 4.89 |
Price/Sales | 3.92 |
Price/Cash Flow | 9.91 |
Price/Earnings
ADMA
Financial Strength
|
Metric
|
ADMA
|
|---|---|
Quick Ratio | 3.73 |
Current Ratio | 6.95 |
Interest Coverage | 29.19 |
Quick Ratio
ADMA
Profitability
|
Metric
|
ADMA
|
|---|---|
Return on Assets (Normalized) | 30.59% |
Return on Equity (Normalized) | 43.25% |
Return on Invested Capital (Normalized) | 35.14% |
Return on Assets
ADMA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Affymax Inc
AFFY
| — | Fsphr | — | |||
| Athersys Inc
ATHXQ
| — | Xjpps | — | |||
| Vertex Pharmaceuticals Inc
VRTX
| Nsdtdbf | Brsdv | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Xzcdqtwzc | Ssqgqg | $64B | |||
| UCB SA
UCBJF
| — | Qrt | $61B | |||
| UCB SA ADR
UCBJY
| — | Rhvwg | $61B | |||
| argenx SE
ARGNF
| — | Nzsrn | $56B | |||
| argenx SE ADR
ARGX
| Swtmhtgpd | Gmmvw | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Zsghylhtv | Bnptyb | $38B | |||
| CSL Ltd
CMXHF
| — | Wlrmt | $36B |
United States